<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
<channel>


<title>aktiencheck.de - Forum - Borregaard ASA</title>
<link>http://www.aktiencheck.de</link>
<description>aktiencheck.de</description>
<language></language>
<copyright>aktiencheck.de</copyright>
<lastBuildDate>Thu, 23 Apr 2026 20:29:38 +0200</lastBuildDate>
<ttl>2</ttl>








<item>
<title>Borregaard (WKN: A1J5TM)</title>
<link>http://www.aktiencheck.de/forum/Borregaard_WKN_A1J5TM-A1J5TM-t550427</link>
<guid>http://www.aktiencheck.de/forum/Borregaard_WKN_A1J5TM-A1J5TM-t550427</guid>
<description>Q4, https://www.finanznachrichten.de/nachrichten-2023-02/58212512-borregaard-asa-ebitda1-of-nok-364-million-in-the-4th-quarter-399.htm


Borregaard ASA: EBITDA1 of NOK 364 million in the 4th quarter
Borregaard's operating revenues reached NOK 1,770 million (NOK 1,446 million)2 in the 4th quarter of 2022. EBITDA1 increased to NOK 364 million (NOK 263 million). BioMaterials and Fine Chemicals had significant result improvements while BioSolutions had a decrease. The net currency impact on EBITDA1 was positive compared with the 4th quarter of 2021.

Increased sales prices in addition to a higher volume and a favourable product mix were the main reasons for the EBITDA1 improvement in BioMaterials. The result improvement in Fine Chemicals was due to increased sales prices and a higher bioethanol sales volume. Reduced margin and volume for traded vanillin products were the main reasons for the EBITDA1 decrease in BioSolutions. Cost increases affected all business areas.

Operating profit rea [&lt;a href=&#034;http://www.aktiencheck.de/forum/Borregaard_WKN_A1J5TM-A1J5TM-t550427&#034;&gt;mehr&lt;/a&gt;]</description>
</item>

</channel>
</rss>







